Alembic Pharmaceuticals Ltd. NSE: APLLTD | BSE: 533573

Slowing Down Stock

In 5 Starfolio Baskets

Download real time

711.20 -18.40 (-2.52%)

New 52W Low today

117.4K

NSE+BSE Volume

NSE 27 Feb, 2026 3:31 PM (IST)

US FDA Approval

Alembic Pharma gets US FDA nod for seizure treatment drug, with a market size of $27 million See details

Alembic Pharma News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Alembic Pharma from all sources in a single place.

Alembic Pharmaceuticals Ltd.

27 Feb 2026, 06:02PM

711.20

-2.52%

AGM

Alembic Pharmaceuticals Ltd - 533573 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

BSE India

Please find attached herewith the Postal Ballot Notice dated 27th February, 2026.

Alembic Pharmaceuticals Ltd.

26 Feb 2026

711.20

-2.52%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Alembic Pharmaceuticals Limited receives USFDA Final Approval for Lamotrigine Orally Disintegrating Tablets USP, 25 mg, 50 mg, 100 mg and 200 mg.

Alembic Pharmaceuticals Ltd.

24 Feb 2026

711.20

-2.52%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Alembic Pharmaceuticals Limited receives USFDA Final Approval for Efinaconazole Topical Solution, 10%.

Alembic Pharmaceuticals Ltd.

18 Feb 2026

711.20

-2.52%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Completion Of United States Food And Drug Administration Inspection At …

BSE India

Completion of USFDA inspection at Company''s Injectable Facility (F-3) at Karakhadi.

Alembic Pharmaceuticals Ltd.

11 Feb 2026

711.20

-2.52%

Earnings Call

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Please find attached herewith the Transcript of Post Result Conference Call held on 05th February, 2026.

Alembic Pharmaceuticals Ltd.

11 Feb 2026

711.20

-2.52%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Please find attached Newspaper Publication

Alembic Pharmaceuticals Ltd.

06 Feb 2026

711.20

-2.52%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Newspaper Publication of Unaudited Financials Results for the Quarter and Nine Months Ended 31st December, 2025

Alembic Pharmaceuticals Ltd.

06 Feb 2026

711.20

-2.52%

Alembic Pharmaceuticals gets nod for generic Parkinson's treatment tablets

Business Standard

Alembic Pharmaceuticals Ltd on Friday said it has received approval from the US health regulator for its generic version of Carbidopa, Levodopa and Entacapone tablets used in treatment of Parkinson's disease. The approval by the US Food & Drug Administration (USFDA) is for the Abbreviated New Drug Application (ANDA) of Carbidopa, Levodopa and Entacapone tablets of strengths 12.5 mg/50 mg/200 mg; 18.75 mg/75 mg/200 mg; 25 mg/100 mg/200 mg; 31.25 mg/125 mg/200 mg; 37.5 mg/150 mg/200 mg; and 50 mg/200 mg/200 mg, Alembic Pharmaceuticals Ltd said in a regulatory filing. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Stalevo tablets of similar strengths of Orion Corporation, it added. Carbidopa, levodopa and entacapone tablets are indicated for the treatment of Parkinson's disease, the company said.

Alembic Pharmaceuticals Ltd. is trading below all available SMAs

Alembic Pharma shares slide 4% on Q3 profit miss; is it a good time to buy?

Business Standard | 06 Feb 2026 1 more

Alembic Pharmaceuticals Ltd.

06 Feb 2026

711.20

-2.52%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Alembic Pharmaceuticals Limited receives USFDA Final Approval for Carbidopa, Levodopa and Entacapone Tablets

Alembic Pharmaceuticals Ltd.

05 Feb 2026

711.20

-2.52%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Change in Directorate

BSE India

Please find attached the intimation of appointment of Mr. Raj Kumar Baheti (DIN:00332079) as Non-Executive Non Independent Director of the Company.

Is Alembic Pharmaceuticals Ltd. worth buying?

242 Votes:

Buy 83.88%

Sell 8.26%

Hold 7.85%

RESEARCH REPORTS

Neutral SEE REPORTS >

Buy SEE REPORTS >